The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Background Pembrolizumab demonstrated durable antitumor activity in 233 patients with
previously treated advanced microsatellite instability high (MSI-H) or mismatch repair …

PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient …

Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …